| Health / Medical Topics |
MET tyrosine kinase inhibitor PF-02341066
Pronunciation
A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma kinase (ALK). It is also being studied in the treatment of other types of cancer. MET tyrosine kinase inhibitor PF-02341066 blocks the protein made by the mutated ALK gene. Blocking this protein may stop the growth and spread of cancer cells. MET tyrosine kinase inhibitor PF-02341066 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called crizotinib, PF-02341066, and Xalkori. (NCI Dictionary)
YOU MAY ALSO LIKE
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor EMD 1214063 selectively binds to MET tyrosine kinase…
An inhibitor of the receptor tyrosine kinase Met (hepatocyte growth factor receptor) with potential antineoplastic activity. MET inhibitor EMD 1204831 selectively binds…
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibitor BMS-777607 binds to c-Met protein, or hepatocyte growth…
This gene plays a regulatory role in the modulation of cell-surface receptors and hepatocyte growth factor interactions.
A semisynthetic estrogen. Metabolized by the liver to ethynyl estradiol, mestranol serves as the estrogen component in several combination oral contraceptives. …
A type of RNA found in cells. Messenger RNA molecules carry the genetic information needed to make proteins. They carry the…
